Genocea Biosciences Inc (GNCA)

5.51
NASDAQ : Health Care
Prev Close 5.39
Day Low/High 5.02 / 5.52
52 Wk Low/High 3.28 / 7.29
Avg Volume 233.10K
Exchange NASDAQ
Shares Outstanding 28.50M
Market Cap 153.64M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

2 'Swing for the Fences' Small Biotechs

2 'Swing for the Fences' Small Biotechs

Genocea Biosciences and Eiger Biopharmaceuticals are high risk/high reward plays.

2 'Swing for the Fences' Small Biotechs

2 'Swing for the Fences' Small Biotechs

Genocea Biosciences and Eiger Biopharmaceuticals are high risk/high reward plays.

Vegas Baby: Rolling '777s' in Biotech

Vegas Baby: Rolling '777s' in Biotech

Three small-cap biotechs with attractive risk/reward profiles.

This Trading-Range Action Is Not Offering Much

This Trading-Range Action Is Not Offering Much

If you want to trade, you have to maintain short timeframes and be ready to flip.

Genocea Awarded World Vaccine Congress 2017 Industry Excellence Award For Best Therapeutic Vaccine For GEN-003 For Genital Herpes

Company highlights its T cell-Directed Genital Herpes and Neoantigen Cancer Vaccine Candidates in two oral presentations

Howard Mayer, M.D., Of Shire, Joins Genocea Biosciences' Board Of Directors

Dr. Mayer brings significant depth of experience in global clinical drug development

RSI Alert: Genocea Biosciences (GNCA) Now Oversold

RSI Alert: Genocea Biosciences (GNCA) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Genocea Congratulates Jessica Baker Flechtner, Ph.D. For Recognition On 2016's 40 Women To Watch Over 40 List

Genocea Congratulates Jessica Baker Flechtner, Ph.D. For Recognition On 2016's 40 Women To Watch Over 40 List

Genocea Chief Scientific Officer honored for innovation in development of novel immunotherapies

Genocea Reports Second Quarter 2016 Financial Results

Genocea Reports Second Quarter 2016 Financial Results

- GEN-003 Phase 2b Viral Shedding Data Expected in September 2016 -

Genocea Biosciences (GNCA) Highlighted As Weak On High Volume

Genocea Biosciences (GNCA) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Genocea Biosciences (GNCA) as a weak on high relative volume candidate

7 Stocks Under $10 Making Big Moves

7 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.